Article
Oncology
Andrea DeCensi, Harriet Johansson, Thomas Helland, Matteo Puntoni, Debora Macis, Valentina Aristarco, Silvia Caviglia, Tania Buttiron Webber, Irene Maria Briata, Mauro D'Amico, Davide Serrano, Aliana Guerrieri-Gonzaga, Ersilia Bifulco, Steinar Hustad, Havard Soiland, Luca Boni, Bernardo Bonanni, Gunnar Mellgren
Summary: Low-dose tamoxifen can reduce the risk of recurrence in non-invasive breast cancer by half without significant adverse events. Most subjects treated with 5 mg/day have endoxifen levels below 9 nM, and there is no significant association with recurrence, indicating that tamoxifen failure is not related to poor drug metabolism.
Review
Oncology
Swaathi Jayaraman, Xinyan Wu, Krishna R. Kalari, Xiaojia Tang, Mary J. Kuffel, Elizabeth S. Bruinsma, Shahrzad Jalali, Kevin L. Peterson, Cristina Correia, Rachel A. Kudgus, Scott H. Kaufmann, Santosh Renuse, James N. Ingle, Joel M. Reid, Matthew M. Ames, Alan P. Fields, Matthew J. Schellenberg, John R. Hawse, Akhilesh Pandey, Matthew P. Goetz
Summary: Endoxifen interacts with protein kinase C beta (PKC beta) to inhibit the activation of protein kinase B alpha or AKT1, thereby suppressing the AKT signaling pathway and inducing apoptosis in breast cancer cells.
Review
Oncology
Tessa A. M. Mulder, Miriam de With, Marzia del Re, Romano Danesi, Ron H. J. Mathijssen, Ron H. N. van Schaik
Summary: Tamoxifen is a crucial adjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer patients, with the conversion to the active metabolite endoxifen mainly depending on the CYP2D6 enzyme. Genetic variations in the CYP2D6 gene can impact endoxifen formation and therapy outcomes, though the correlation between CYP2D6 genotype and clinical outcome remains debated. Recent developments from 2018 to 2020 shed light on this ongoing debate.
Article
Pharmacology & Pharmacy
Gabriel Ramirez, Marcelo Vital, Carolina Vergara, Florencia Carusso, Florencia Neffa, Adriana Della Valle, Patricia Esperon
Summary: This study reports the distribution of CYP2D6 gene allele frequencies and their influence on clinical outcomes in a group of breast cancer patients from Uruguay. The results indicate that CYP2D6 gene polymorphisms do not have an impact on clinical outcomes.
PERSONALIZED MEDICINE
(2023)
Article
Multidisciplinary Sciences
Stefan Rehnmark, Ivan Shabo, Hakan Randahl, Yvonne Wengstrom, Per Rydberg, Elham Hedayati
Summary: This study aimed to compare three blood sampling methods for measuring the concentrations of Tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen. The results showed significant differences in the concentrations of Z-endoxifen and 4-hydroxytamoxifen between capillary and venous blood samples, but no significant differences in Tamoxifen concentrations. Additionally, the concentrations remained relatively stable after storing the samples for 14 days.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Sixten Harborg, Deirdre Cronin-Fenton, Maj-Britt Raaby Jensen, Thomas P. Ahern, Marianne Ewertz, Signe Borgquist
Summary: Clinical studies confirm that obesity is a risk factor for recurrence in postmenopausal women with hormone receptor-positive breast cancer. Evidence suggests that women with obesity do not obtain similar protection from aromatase inhibitors as women with healthy weight.
Article
Oncology
Takuji Iwase, Shigehira Saji, Kotaro Iijima, Kenji Higaki, Shoichiro Ohtani, Yasuyuki Sato, Yasuo Hozumi, Yoshie Hasegawa, Yasuhiro Yanagita, Hiroyuki Takei, Maki Tanaka, Hideji Masuoka, Masahiko Tanabe, Chiyomi Egawa, Yoshifumi Komoike, Toshitaka Nakamura, Hiroshi Ohtsu, Hirofumi Mukai
Summary: This study investigated the effects of extending the treatment with an aromatase inhibitor for 10 years on disease-free survival in postmenopausal hormone receptor-positive breast cancer patients. The results showed that extending the treatment with an aromatase inhibitor for an additional 5 years improved disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Tom van den Bosch, Oscar M. Rueda, Carlos Caldas, Louis Vermeulen, Daniel M. Miedema
Summary: This study found that low-risk breast cancer patients identified using chromosomal copy-number ITH do not benefit from adjuvant endocrine therapy.
BRITISH JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
David R. Nelson, Jacqueline Brown, Aki Morikawa, Michael Method
Summary: This study aimed to investigate the impact of breast cancer subtypes on breast cancer-specific mortality in early breast cancer (EBC) and the incidence of high-risk indicators for recurrence. It also examined the mortality risk difference between patients who met/did not meet the high-risk criteria defined in the monarchE trial.
Article
Medicine, General & Internal
Timothy J. Whelan, Sally Smith, Sameer Parpia, Anthony W. Fyles, Anita Bane, Fei-Fei Liu, Eileen Rakovitch, Lynn Chang, Christiaan Stevens, Julie Bowen, Sawyna Provencher, Valerie Theberge, Anna Marie Mulligan, Zuzana Kos, Mohamed A. Akra, K. David Voduc, Tarek Hijal, Ian S. Dayes, Gregory Pond, James R. Wright, Torsten O. Nielsen, Mark N. Levine
Summary: Among women with T1N0 grade 1 or 2 luminal A breast cancer who had undergone breast-conserving surgery and received endocrine therapy, the incidence of local recurrence at 5 years was low without radiotherapy.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Vasily Giannakeas, David W. Lim, Steven A. Narod
Summary: Women with unilateral breast cancer have an annual risk of contralateral breast cancer similar to 0.4% per year, which persists over the 25-year follow-up period. The 25-year cumulative risk of contralateral invasive breast cancer was 9.9%, with variations based on age of diagnosis, time since diagnosis, race, and ER status of the first cancer.
BRITISH JOURNAL OF CANCER
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Thi Xuan Mai Tran, Soyeoun Kim, Huiyeon Song, Eunhye Lee, Boyoung Park
Summary: Breast density changes over time are associated with breast cancer risk in both premenopausal and postmenopausal women. Continuous increase in breast density increases the future risk of breast cancer, while continuous decrease in breast density is associated with a lower risk.
Article
Pharmacology & Pharmacy
Shishi Luo, Ruomu Jiang, Joseph J. Grzymski, William Lee, James T. Lu, Nicole L. Washington
Summary: Genomic-guided pharmaceutical prescribing is increasingly important, and accurate genotyping of pharmacogenomic genes can be challenging due to their complex genetic architecture. The Helix PGx database provides frequency data for CYP2C9, CYP2C19, CYP2D6, and CYP4F2, demonstrating high diversity in CYP2D6 and higher frequency of rare alleles in non-European populations. Most individuals in the cohort carry high-risk variants in pharmacogenes, suggesting that screening these genes could impact a significant portion of the general population.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Medicine, Research & Experimental
Megan L. Kruse, Mona Patel, Jeffrey McManus, Yoon-Mi Chung, Xiuxiu Li, Wei Wei, Peter S. Bazeley, Fumihiko Nakamura, Aimalie Hardaway, Erinn Downs, Sarat Chandarlapaty, Mathew Thomas, Halle C. F. Moore, George T. Budd, W. H. Wilson Tang, Stanley L. Hazen, Aaron Bernstein, Serena Nik-Zainal, Jame Abraham, Nima Sharifi
Summary: The study found that homozygous inheritance of the adrenal-permissive HSD3B1(1245C) is associated with postmenopausal estrogen receptor-positive (ER-positive) breast cancer. The genotype frequency is higher in postmenopausal White women with estrogen-driven breast cancer compared to ER-negative breast cancer and the general population. Circulating androstenedione concentration is also elevated with the adrenal-permissive genotype.
Article
Radiology, Nuclear Medicine & Medical Imaging
Max A. A. Ragusi, Bas H. M. van der Velden, Carla Meeuwis, Eric Tetteroo, Emile G. Coerkamp, Thiemo J. A. van Nijnatten, Frits H. Jansen, Elian J. M. Wolters-van der Ben, Lisa Jongen, Fleur van Raamt, Monique D. Dorrius, Janneke Verloop, Max A. Viergever, Ruud M. Pijnappel, Sjoerd G. Elias, Kenneth G. A. Gilhuijs
Summary: A multicenter retrospective cohort study was conducted to confirm the association between contralateral parenchymal enhancement (CPE) and long-term survival in patients with ER-positive and HER2-negative breast cancer. The study also aimed to investigate the relationship between CPE and endocrine therapy effectiveness.
